Anti-IL6 Receptor Monoclonal Antibody Therapy in NMO. Takashi Yamamura (Japan)

被引：0
|
作者：
Yamamura, Takashi [1 ]
机构：
[1] NCNP, Natl Inst Neurosci, Dept Immunol, Multiple Sclerosis Ctr, Tokyo, Japan
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
L-1
引用
收藏
页码：396 / 396
页数：1
相关论文
共 50 条
  • [21] Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: Effects on soluble IL6 receptor and soluble gp130
    Van Zaanen, HCT
    Lokhorst, HM
    Aarden, LA
    Rensink, HJAM
    Warnaar, SO
    Van Oers, MHJ
    LEUKEMIA & LYMPHOMA, 1998, 31 (5-6) : 551 - 558
  • [22] Catch-up growth in severe systemic-onset juvenile idiopathic arthritis: Long-term treatment with humanized anti-IL6 receptor monoclonal antibody
    Imagawa, T
    Miyamae, T
    Umebayashi, H
    Kurosawa, R
    Katakura, S
    Mori, M
    Nishimoto, N
    Yokota, S
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S91 - S92
  • [23] Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies.
    vanZaanen, HCT
    Koopmans, RP
    Aarden, LA
    Rensink, HJAM
    Stouthard, JML
    Warnaar, SO
    Lokhorst, HM
    vanOers, MHJ
    BLOOD, 1995, 86 (10) : 727 - 727
  • [24] Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis
    Blair, Joseph Patrick Michele
    Bager, Cecilie
    Tang, Man Hung Eric
    Karsdal, Morten
    Bay-Jensen, Anne
    Brunak, Soren
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [25] ANTI-IL-6 RECEPTOR ANTIBODY (TOCILIZUMAB): A B CELL TARGETING THERAPY
    Snir, A.
    Kessel, A.
    Haj, T.
    Rosner, I
    Rozenbaum, M.
    Slobodin, G.
    Toubi, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70
  • [26] ANTI-IL-6 RECEPTOR ANTIBODY (TOCILIZUMAB): A B CELL TARGETING THERAPY
    Toubi, E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 152 - 152
  • [27] Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis
    J. P. M. Blair
    A.-C. Bay-Jensen
    M. H. Tang
    P. Frederiksen
    C. Bager
    M. Karsdal
    S. Brunak
    Scientific Reports, 10
  • [28] Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis
    Blair, J. P. M.
    Bay-Jensen, A. -C.
    Tang, M. H.
    Frederiksen, P.
    Bager, C.
    Karsdal, M.
    Brunak, S.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [29] Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy
    Snir, A.
    Kessel, A.
    Haj, T.
    Rosner, I.
    Slobodin, G.
    Toubi, E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (04) : 697 - 700
  • [30] Clinical Efficacy of Anti-IL-6 Receptor Monoclonal Antibody Tocilizumab in Patients with Neuromyelitis Optica
    Araki, Manabu
    Matsuoka, Takako
    Aranami, Toshimasa
    Nakamura, Masakazu
    Okamoto, Tomoko
    Murata, Miho
    Miyake, Sachiko
    Yamamura, Takashi
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 911 - 912
12345